China-Biotics, Inc. Announces Conference Call to Discuss Second Quarter FY 2008 Results
Hosting the call will be Jinan Song, Chairman and Chief Executive Officer,Raymond Li, Chief Financial Officer, and Henry Tai, Vice President ofCorporate Development.
To participate in the event by telephone, please dial (800) 374-0113 fiveto 10 minutes prior to the start time (to allow time for registration) andreference the conference ID 23639406. International callers should dial (706)758-9607.
A digital replay of the call will be available on Wednesday, November 14at approximately 12:00 p.m. Eastern Time through Wednesday, November 21 atmidnight Eastern Time. To listen to the replay dial (800) 642-1687 and enterthe conference ID number 23639406. International callers should dial (706)645-9291 and enter the same conference ID number.
The conference call will also be webcast live over the Internet and can beaccessed by all interested parties by using the following link:http://phx.corporate-ir.net/playerlink.zhtml?c=192711&s=wm&e=1689295 . Tolisten to the call, please visit this link at least 15 minutes prior to thestart of the call to register, download and install any necessary audiosoftware. For those unable to participate during the live webcast, it will bearchived using the same link for 90 days.
About China-Biotics, Inc.
China-Biotics, Inc. ("China-Biotics," "the Company"), a leadingmanufacturer of biotechnology products and supplements, engages in theresearch, development, marketing and distribution of probiotics dietarysupplements. Through its wholly owned subsidiary, Shanghai ShiningBiotechnology Co., Ltd., the Company has operations in Shanghai. Itsproprietary product portfolio contains live microbial nutritional supplementsunder the "Shining" brand. Currently, the products are sold OTC through largedistributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang.China-Biotics plans to launch 300 Shining brand stores in major cities inChina during the next two years. The Company's flagship product, "ShiningEssence," was approved by the Chinese Ministry of Health for production and tomarket as a health product in August 2000, and it has been a profit driversince its launch in Shanghai in April 2001. Currently, China-Biotics isstrategically expanding its production capacity of probiotics to meet growingdemand in the bulk additive market.
Safe Harbor Statement Under the Private Securities Litigation Reform Actof 1995: Any statements set forth above that are not historical facts areforward-looking statements that involve risks and uncertainties that couldcause actual results to differ materially from those in the forward-lookingstatements. Such factors include, but are not limited to, the Company'sability to market existing and new products, ability to access to capital forexpansion, and changes from anticipated levels of sales, future national orregional economic and competitive conditions, market acceptance of its retailstore concept, changes in relationships with customers, dependence on itsflagship product profits and other factors detailed from time to time in theCompany's filings with the United States Securities and Exchange Commissionand other regulatory authorities. The Company undertakes no obligation topublicly update or revise any forward-looking statements, whether as a resultof new information, future events or otherwise.For more information, please contact: CCG Elite Investor Relations Crocker Coulson, President Tel: +1-646-213-1915 (Ne
You May Also Like